1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Autoimmune Disease Therapeutics to 2016

Autoimmune Disease Therapeutics to 2016

  • May 2012
  • -
  • Greystone Research Associates

As a group, autoimmune diseases represent one of the most intractable families of conditions facing medical science. The complexities and genetic underpinnings of the human immune response result in a set of disease targets that are at once physiologically ubiquitous and highly individualized. Until recently, autoimmune disease patients were given little hope for an effective treatment. But the convergence an of improved understanding of autoimmune disease mechanisms and the availability of recombinant cytokines has led to systemic treatments that, while not devoid of side effects, have demonstrated the ability to control autoimmune reactions in a significant number of patients. A number of potentially important pipeline drugs hold the promise of future improvements in outcomes for autoimmune disease patients. This study analyzes current autoimmune therapeutics and assesses the next-generation of candidates and their probable impact on treatment options and the competitive landscape.

Highlights

• Analyzes current therapeutic options for autoimmune diseases, and evaluates emerging therapeutic candidates and assesses their commercial potential
• Assesses existing and evolving immune disease mechanisms and treatment strategies
• Analyzes more than two dozen existing and emerging autoimmune disease targets and target-specific therapeutic drug products
• Evaluates regional and global opportunities for autoimmune therapeutics
• Provides market data and forecasts for six major autoimmune disease segments to 2016

Table Of Contents

Autoimmune Disease Therapeutics to 2016
Executive Summary

Autoimmune Therapeutics Segment Dynamics

Sector Market Dynamics
Patient Demographics and Growth
Chronic Disease and Self-administration
Managed Care and Prescribing Trends
Factors Limiting Growth
Industry Alignment and Competitive Landscape

Autoimmune Therapeutic Market Assessments

Arthritis
Disease Forms and Immune Mechanisms
Therapeutic Strategies
Disease Demographics and Growth
Key Approved Therapies
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Crohn's Disease
Disease Incidence and Demographics
Current Generation Treatment Options
Therapies in Development
Market Factors
Commercial Outlook and Forecasts

Diabetes
Restoring Islet Cell Function
Therapies in Development
Commercial Outlook and Forecasts

Lupus
The Ongoing Unmet Need
Pipeline Candidates - A Ray of Hope
Market Factors
The Potential for a Lupus-specific Therapy
Commercial Outlook and Forecasts

Multiple Sclerosis
Disease Mechanisms and Therapeutic Strategies
The Market Opportunity
Competitive Landscape
Development-stage Candidate Assessment
Market Factors
Commercial Outlook and Forecasts

Psoriasis
Therapeutic Options and Expanded Indications
Prescribing Trends and Drug Efficacy
Market Sector Factors
Development-stage Candidate Assessment
Commercial Outlook and Forecasts

Market Factors
Risk Factors
Clinical Trial Factors
Product Issues

Autoimmune Therapeutics - Company Profile

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Dyslipidaemia: KOL Insight

Dyslipidaemia: KOL Insight

  • $ 8 085
  • Industry report
  • March 2016
  • by Firstword Pharma

Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have ...

COPD: KOL Insight

COPD: KOL Insight

  • $ 8 085
  • Industry report
  • April 2016
  • by Firstword Pharma

Is the COPD treatment market poised for a fundamental shift? After years of dominance by a handful of brands, change is in the air for COPD treatment. Will deep set preferences finally be overturned, ...

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

  • $ 6 995
  • Industry report
  • April 2016
  • by GBI Research

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Canada

  • June 2016
    35 pages
  • Therapy  

    Targeted Therap...  

    Chemotherapy  

  • Canada  

View report >

Anti-Infective Market in Europe

  • June 2016
    11 pages
  • Anti-Infective  

  • Europe  

    World  

View report >

Dysfunction Drug Market and Diabetes Statistics in the UK and the US - Forecast

  • June 2016
    6 pages
  • Dysfunction Dru...  

    Therapy  

    Hormone  

  • United Kingdom  

    United States  

View report >

Related Market Segments :

Therapy
Autoimmune Disease

ref:plp2012

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.